A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye

NCT ID: NCT05201170

Last Updated: 2024-10-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 575 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-12-30
• Study Completion Date: 2023-11-21

Brief Summary

This is a multi-center, double-masked, randomized, vehicle-controlled study testing PL9643, an ophthalmic solution to determine if safe and efficacious for dry eye patients.

After a 2-week run-in period, patients will be randomized equally to the PL9643 ophthalmic solution or vehicle ophthalmic solution administered bilaterally three times a day for 12 weeks.

A Data Monitoring Committee was engaged to review interim data.

Detailed Description

This is a multi-center, double-masked, randomized, vehicle-controlled study testing PL9643, an ophthalmic solution, to determine the safety and efficacy against a vehicle in dry eye patients.

During a 2-week/14-day study run-in period (for the purpose of subject selection) prior to randomization, all subjects will receive Vehicle Ophthalmic Solution (vehicle) bilaterally three times a day. Randomization will then occur in a 1:1 ratio where patients will be assigned to receive PL9643 ophthalmic solution given bilaterally three times a day or vehicle ophthalmic solution administered bilaterally three times a day. The treatment period is 12 weeks.

Conditions

Dry Eye; Dry Eye Syndromes

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

PL9643 Ophthalmic Solution

PL9643 ophthalmic solution bilaterally three times a day.

Group Type: EXPERIMENTAL

PL9643 Ophthalmic Solution

Intervention Type: DRUG

Ophthalmic Solution

Vehicle Ophthalmic Solution

Vehicle ophthalmic solution bilaterally three times a day.

Group Type: ACTIVE_COMPARATOR

Vehicle Ophthalmic Solution

Intervention Type: DRUG

Ophthalmic Solution

Interventions

Vehicle Ophthalmic Solution

Ophthalmic Solution

Intervention Type: DRUG

PL9643 Ophthalmic Solution

Ophthalmic Solution

Intervention Type: DRUG

Other Intervention Names

Control; Active study medication

Eligibility Criteria

Inclusion Criteria

1. Be at least 18 years of age;

2. Provide written informed consent;

3. Be willing and able to comply with all study procedures;

4. Have a patient-reported history of dry eye for at least 5 years prior to Visit 1;

5. Have a history of use or desire to use eye drops for dry eye symptoms within 6 months of Visit 1;

6. Have a best corrected visual acuity (BCVA) of 0.7 logarithm of the minimum angle of resolution (logMAR) or better (Snellen equivalent score of 20/100 or better) in each eye at Visit 1;

7. Have an inferior fluorescein corneal staining score > 1 at both Visits 1 and 2 Pre-CAE®;

8. Have an Eye Discomfort from the Visual Analog Scale (VAS) ≥25 at both Visits 1 and 2 Pre-CAE®;

9. Report a score of ≥ 2 according to the Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire in at least one of the dry eye symptoms at Visits 1 and 2 Pre-CAE®;

10. Have a Schirmer's Test score of ≤ 10 mm and ≥ 1 mm at Visits 1 and 2;

11. Have a corneal fluorescein staining score of ≥ 2 in any corneal region (inferior, central or superior) according to the Ora Calibra® Corneal and Conjunctival Staining Scale for Grading of Fluorescein Staining in at least one eye at Visits 1 and 2 Pre-CAE®;

12. Have a conjunctival redness score ≥ 1 according to the Ora Calibra® Conjunctival Redness for Dry Eye Scale in at least one eye at Visits 1 and 2 Pre-CAE®;

13. Demonstrate in the same eye(s) a response to the CAE®at Visits 1 and 2 as defined by:

1. Having at least a ≥1 point increase in fluorescein staining in the inferior region in at least one eye following CAE® exposure;

2. Reporting an Ocular Discomfort score ≥3 at 2 or more consecutive time points in at least one eye during CAE® exposure (if a subject has an Ocular Discomfort rating of 3 at time = 0 for an eye, s/he must report an Ocular Discomfort rating of 4 for two consecutive measurements for that eye). Note: a subject cannot have an Ocular Discomfort score of 4 at time = 0);

14. Have at least one eye, the same eye, satisfy all criteria for 7, 8, 9, 10, 11, 12 and 13 above;

15. A negative urine pregnancy test if female of childbearing potential (those who are not surgically sterilized [bilateral tubal ligation, hysterectomy or bilateral oophorectomy] or post-menopausal [12 months after last menses]) and must use adequate birth control through the study period. For non-sexually active females, abstinence may be regarded as an adequate method of birth control

Exclusion Criteria

1. Have any clinically significant slit-lamp findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction, lid margin inflammation, or active ocular allergies that require therapeutic treatment, and/or in the opinion of the Investigator may interfere with study parameters;

2. Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at Visit 1 or Visit 2;

3. Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses during the study;

4. Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the last 12 months;

5. Have used Restasis®, Xiidra®, Cequa®, or Eysuvis® within 60 days of Visit 1;

6. Have had any ocular and/or lid surgeries in the past 6 months or have any planned ocular and/or lid surgeries over the study period;

7. Have had any laser procedures (e.g. YAG capsulotomy) in the past 3 months;

8. Be using or anticipate using temporary punctal plugs during the study that have not been stable within 30 days of Visit 1;

9. Be currently taking any topical ophthalmic prescription (including medications for glaucoma) or over-the-counter solutions, artificial tears, gels or scrubs, and cannot discontinue these medications for the duration of the trial (excluding medications allowed for the conduct of the study); the respective wash-out periods are required for thefollowing medications:

1. Ocular, oral or nasal antihistamines: 72 hours prior to Visit 1 and during the study.

2. Oral aspirin or aspirin-containing products allowed if dose has been stable over past 30 days prior to Visit 1 and no change in dose is anticipated during the study period

3. Corticosteroids or mast cell stabilizers (including ocular): 14 days prior to Visit 1

4. Any medication (oral or topical) known to cause ocular drying that has not been administered as a stable dose for at least 30 days prior to Visit 1 and during the study

5. All other topical ophthalmic preparations (including artificial tear substitutes) other than the study drops: 72 hours prior to Visit 1

10. Have an uncontrolled systemic disease;

11. Be a woman who is pregnant, nursing, or planning a pregnancy;

12. Be unwilling to submit a urine pregnancy test at Visit 1 and Visit 6 (or early termination visit) if of childbearing potential. Non-childbearing potential is defined as a woman who is permanently sterilized (e.g., bilateral tubal ligation, hysterectomy or bilateral oophorectomy), or is post-menopausal (without menses for 12 consecutive months);

13. Be a woman of childbearing potential who is not using an acceptable means of birth control; acceptable methods of contraception include: hormonal - oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as a diaphragm or condom; intrauterine device; or surgical sterilization of partner. For non-sexually active females, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the study, she must agree to use adequate birth control as defined above for the remainder of the study;

14. Have a known allergy and/or sensitivity to the test article or its components;

15. Have a condition or be in a situation which the Investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study;

16. Have used an investigational drug or device within 30 days of Visit 1 unless the Investigator or Sponsor deems a washout period of up to 60 days is required;

17. Participated in a previous clinical study involving PL9643;

18. Be unable or unwilling to follow instructions, including participation in all study assessments and visits.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Palatin Technologies, Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Brian Dodge

Role: STUDY_DIRECTOR

Palatin

Locations

Global Research Management

Glendale, California, United States

Eye Research Foundation

Newport Beach, California, United States

East West Eye Institute

Torrance, California, United States

Pankratz Eye Institute

Columbus, Indiana, United States

Michael Washburn Center for Ophthalmic Research, LLC

Indianapolis, Indiana, United States

Kentucky Eye Institute

Lexington, Kentucky, United States

Butchertown Clinical Trials

Louisville, Kentucky, United States

Andover Eye Associates

Andover, Massachusetts, United States

Center for Sight

Las Vegas, Nevada, United States

Mint Hill

Mint Hill, North Carolina, United States

Core, Inc

Shelby, North Carolina, United States

Bergstrom Eye research, LLC

Fargo, North Dakota, United States

Erie Retina Research, LLC

Erie, Pennsylvania, United States

Advancing Vision Research

Goodlettsville, Tennessee, United States

Total Eye Care, PA

Memphis, Tennessee, United States

Advancing Vision Research

Smyrna, Tennessee, United States

Austin Clinical Research

Austin, Texas, United States

Axis Clinical

Dallas, Texas, United States

Countries

United States

Other Identifiers

PL9643-301

Identifier Type: -

Identifier Source: org_study_id